Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA launches 5-year initiative for rare neurodegenerative diseases 

By Brian Buntz | June 24, 2022

FDA logoFDA has unveiled its Action Plan for Rare Neurodegenerative Diseases, including amyotrophic lateral sclerosis (ALS).

The plan will involve the use of public-private partnerships and incorporate feedback from patients. The initiative will encompass regulatory science initiatives, changes to existing programs and new policy initiatives.

Milestones of the initiative include the creation of an FDA rare neurodegenerative diseases task force and public-private partnerships for rare neurodegenerative diseases in the fiscal year 2022. In addition, from fiscal years 2022 to 2026, the plan aims to develop disease-specific science strategies.

The initiative is an outgrowth of a Public Law 117-79, the “Accelerating Access to Critical Therapies for ALS Act” (ACT for ALS) President Biden signed into law on December 23, 2021.

“We recognize the urgent need for new treatments that can both improve and extend the lives of people diagnosed with these diseases,” said FDA Commissioner Dr. Robert M. Califf in a news release. “To face that challenge and to accelerate drug development, we need innovative approaches to better understand these diseases while also building on current scientific and research capabilities.”

For ALS in particular, FDA will aim to help understand disease pathogenesis and natural history, support patient access to new drugs and bolster relevant clinical trial infrastructure.

Research on ALS and other neurodegenerative diseases has ramped up recently.

In February, Oregon State University (OSU) scientists announced the discovery of a new class of potential drug targets for diseases like Alzheimer’s, Parkinson’s and ALS.

On June 1, Irvine, California-based Eledon Pharmaceuticals announced promising topline results from a Phase 2a study of tegoprubart. It was the first time an investigational drug showed reduced inflammatory biomarkers associated with ALS progression.

More recently, Amylyx scored approval with conditions from Health Canada for ALS therapy Albrioza (AMX0035).


Filed Under: Neurological Disease
Tagged With: ALS, amyotrophic lateral sclerosis, FDA, neurodegenerative diseases
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Beacon Biosignals
How EEG data and machine learning can inform drug development
depression
The pandemic is fueling the demand for natural alternatives to antidepressants
Beta amyloid plaque
Fluoride nanoparticles could hold promise in treating Alzheimer’s
Astellas Pharma in the Drug Discovery & Development Pharma 50
FDA places clinical hold on Astellas clinical trial focused on Pompe disease

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50